Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease-Reference-Cited by-同舟云学术

Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease

Published:2019-06-01 Issue:11 Volume:58 Page:1587-1591
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nagayama Izumi¹,Masuda Takahiro¹,Nakagawa Saki¹,Murakami Takuya¹,Ohara Ken¹,Matsuoka Ryo²,Kobayashi Takahisa¹,Maeshima Akito¹,Akimoto Tetsu¹,Saito Osamu¹,Muto Shigeaki¹,Nagata Daisuke¹

Affiliation:

1. Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan

2. Department of Clinical Engineering, Jichi Medical University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/11/58_2174-18/_pdf

Reference22 articles.

1. 1. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 119: S26-S36, 2006.

2. 2. Mori T, Ohsaki Y, Oba-Yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatol Res 47: 11-22, 2017.

3. 3. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13: 599-608, 2007.

4. 4. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V (2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288-294, 2000.

5. 5. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61: 169-174, 2013.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolvaptan therapy for edema in patients with chronic kidney disease;Clinical Nephrology;2024-06-01

2. Effect of furosemide on body composition and urinary proteins that mediate tubular sodium and sodium transport—A randomized controlled trial;Physiological Reports;2020-12-23

3. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis;Hepatology Research;2020-09-26

4. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease;Diabetology & Metabolic Syndrome;2020-05-01

5. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study;BMC Gastroenterology;2020-03-05